Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

SpringWorks Therapeutics, Inc. - common stock (NQ:SWTX)

46.27 +0.16 (+0.35%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about SpringWorks Therapeutics, Inc. - common stock

< Previous 1 2 3 4 5 6 Next >
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2022
Via Benzinga
How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market
Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years. 
Via Benzinga
Analyst Ratings for SpringWorks Therapeutics
Within the last quarter, SpringWorks Therapeutics (NASDAQ:SWTX) has observed the following analyst ratings: 
Via Benzinga
SpringWorks Shares Pop After Expanded Multiple Myeloma Pact With GSK
Via Benzinga
Analyst Ratings for SpringWorks Therapeutics
  Within the last quarter, SpringWorks Therapeutics (NASDAQ:SWTX) has observed the following analyst ratings: 
Via Benzinga
SpringWorks Therapeutics to Participate in the Evercore ISI 5th Annual HealthCONx Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics: Q3 Earnings Insights
SpringWorks Therapeutics (NASDAQ:SWTX) reported its Q3 earnings results on Thursday, November 3, 2022 at 06:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
SpringWorks Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics Announces Dosing of First Patient in Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
HC Wainwright Believes Ayala's Initial Cancer Data Is Encouraging
Via Benzinga
Central Nervous System Disorders Therapeutics Market Expected to Reach $159 Billion by 2028
Palm Beach, FL –– October 12, 2022 – FinancialNewsMedia.com News Commentary – The COVID pandemic has not only had a negative effect on most markets but it has also spurred growth in several worldwide... 
Via FinancialNewsMedia
Exposures COVID-19
NIO, Lucid Group And Other Big Gainers From Monday
U.S. stocks closed higher with the Dow Jones surging more than 200 points on Monday. Here is the list of some big stocks moving higher in the previous session. 
Via Benzinga
Why Tuesday Morning Shares Tumbled 31%; Here Are 66 Biggest Movers From Yesterday
Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 101.3% to settle at $0.5558 on Monday after the company announced a 1-for-30 reverse stock split. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
  
Via Benzinga
Why Invitae Climbed Around 279%; Here Are 98 Biggest Movers From Yesterday
Gainers Invitae Corporation (NYSE: NVTA) surged 278.5% to close at $8.63 after the company reported better-than-expected Q2 EPS. 
Via Benzinga
Why Plug Power Is Trading Higher By Around 14%, Here Are 73 Stocks Moving In Wednesday's Mid-Day Session
Gainers BioAtla, Inc. (NASDAQ: BCAB) gained 50.1% to $5.42 following Q2 results. Euro Tech Holdings Company Limited (NASDAQ: CLWT) surged 39.5% to $2.0380. 
Via Benzinga
SpringWorks Therapeutics: Q2 Earnings Insights
  SpringWorks Therapeutics (NASDAQ:SWTX) reported its Q2 earnings results on Thursday, August 4, 2022 at 06:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Beyond Meat, Canoo, Veru And More: 12 Short Squeeze Candidates To Watch
One of the most powerful tradable market events is a short squeeze, so traders are always on the lookout for the next short squeeze candidate. S3 Partners analyst Ihor Dusaniwsky has just released a... 
Via Benzinga
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in SpringWorks Therapeutics, Inc. with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
SpringWorks Therapeutics Shares Jump On HC Wainwright Bullish Pitch
HC Wainwright points out that investors are enthusiastic about SpringWorks Therapeutics Inc (NASDAQ: SWTX) nirogacestat clinical profile for desmoid tumors after the R&D day held last week. 
Via Benzinga
Mid-Afternoon Market Update: Dow Gains 500 Points; Red Robin Gourmet Burgers Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining 500 points on Friday. 
Via Benzinga
70 Biggest Movers From Friday
Gainers Avadel Pharmaceuticals plc (NASDAQ: AVDL) shares climbed 133.6% to close at $2.50 on Friday. Avadel Pharmaceuticals shares dipped 68% on Thursday after announcing new FDA request for... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 59 stocks hit new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers 
Via Benzinga
Dow Up Nearly 300 Points, Eyeing Seventh-Straight Daily Win
An upbeat core personal consumption expenditures price index for April is boosting investor sentiment at midday after it showed slowing inflation. 
Via Talk Markets
Mid-Morning Market Update: Markets Open Higher; US Goods Trade Deficit Narrows In April
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Friday. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
We're starting the final day of trading for the week with a breakdown of the biggest pre-market stock movers for Friday! 
Via InvestorPlace
20 Stocks Moving in Friday's Pre-Market Session
Gainers Adicet Bio, Inc. (NASDAQ: ACET) rose 16% to $11.90 in pre-market trading after reporting positive clinical update from ADI-001 Phase 1 Trial in relapsed/refractory Non-Hodgkin’s Lymphoma. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.